Friday 6 November 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue: +1.44%
EPS: −21.6%
Free cash flow: −25.3%
Total debt: +3.04%

Quarter to September 2026, against a year earlier

43.09 1.55 −3.47%

Follow BSX

Alert me

Market cap: $64.7B
P/E: 18.7×
Fwd P/E: 17.0×
Dividend yield: —
F-score: 7/9
Altman Z: 5.41
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Boston Scientific Corporation (BSX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Cardiovascular	13,250	66.01%
MedSurg	6,824	33.99%
Gross margin		69.01%
Operating margin		17.99%
Pre-tax margin		16.86%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Interventional Cardiology & Vascular Therapies	4,639 23.11%	4,199 25.07%	3,791 26.62%	2,228 17.57%	2,209 18.58%	1,975 19.92%	—	—	—	—
Electrophysiology	3,325 16.56%	1,904 11.37%	800 5.62%	585 4.61%	365 3.07%	287 2.90%	329 3.06%	311 3.17%	278 3.07%	243 2.90%
Endoscopy	2,916 14.53%	2,687 16.04%	2,482 17.43%	2,221 17.51%	2,141 18.01%	1,780 17.96%	1,894 17.64%	1,762 17.94%	1,619 17.89%	1,440 17.17%
Urology	2,709 13.50%	2,200 13.14%	1,964 13.79%	1,773 13.98%	1,583 13.32%	1,286 12.97%	1,413 13.16%	1,245 12.67%	1,124 12.42%	1,005 11.98%
Cardiac Rhythm Management	2,332 11.62%	2,279 13.61%	2,218 15.58%	2,100 16.56%	2,019 16.98%	1,704 17.19%	1,939 18.06%	1,951 19.86%	1,895 20.94%	1,850 22.06%
Watchman	1,958 9.75%	1,516 9.05%	1,274 8.95%	1,019 8.04%	829 6.97%	324 3.27%	—	—	—	—
Neuromodulation	1,199 5.97%	1,106 6.60%	976 6.85%	917 7.23%	909 7.65%	761 7.68%	873 8.13%	779 7.93%	635 7.02%	556 6.63%
Interventional Oncology & Embolization	996 4.96%	856 5.11%	736 5.17%	—	—	—	—	—	—	—
Peripheral Interventions	—	—	—	1,899 14.97%	1,820 15.31%	1,577 15.91%	1,392 12.97%	1,187 12.08%	1,081 11.95%	1,011 12.06%
Other	—	—	—	(60) (0.47%)	13 0.11%	219 2.21%	81 0.75%	—	—	—
Global Interventional Cardiology (IC) Reporting Unit	—	—	—	—	—	—	2,816 26.23%	2,590 26.37%	2,419 26.74%	2,281 27.20%
Cardiology	—	—	—	5,932	5,422	4,290	—	—	—	—
Revenue	20,074	16,747	14,240	12,682	11,888	9,913	10,735	9,823	9,048	8,386

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2018	FY2017	FY2016	FY2015	FY2010	FY2009	FY2008
Cardiovascular	13,250 66.01%	10,755 64.22%	8,819 61.93%	7,831 61.75%	7,242 60.92%	5,866 59.17%	3,777 38.45%	3,500 38.68%	3,292 39.26%	2,937 39.28%	3,271 41.90%	3,520 42.99%	3,563 44.26%
MedSurg	6,824 33.99%	5,993 35.79%	5,422 38.08%	4,911 38.72%	4,633 38.97%	3,827 38.61%	3,007 30.61%	2,742 30.31%	2,445 29.16%	2,500 33.44%	—	—	—
Rhythm and Neuro	—	—	—	—	—	—	3,041 30.96%	2,808 31.03%	2,649 31.59%	—	—	—	—
Rhythm Management	—	—	—	—	—	—	—	—	—	2,040 27.28%	—	—	—
Cardiac Rhythm Management	—	—	—	—	—	—	—	—	—	—	2,180 27.93%	2,413 29.47%	2,286 28.40%
Endoscopy	—	—	—	—	—	—	—	—	—	—	1,079 13.82%	1,006 12.29%	943 11.71%
Urology Women's/Health	—	—	—	—	—	—	—	—	—	—	481 6.16%	456 5.57%	431 5.35%
Neurovascular	—	—	—	—	—	—	—	—	—	—	340 4.36%	348 4.25%	360 4.47%
Neuromodulation	—	—	—	—	—	—	—	—	—	—	304 3.89%	285 3.48%	245 3.04%
Electrophysiology	—	—	—	—	—	—	—	—	—	—	147 1.88%	149 1.82%	153 1.90%
Other, not broken out	—	—	—	—	—	220 2.22%	—	—	—	—	—	—	69 0.86%
BSX Reportable Segments	—	—	—	—	—	—	9,823	9,048	—	—	—	—	—
Revenue	20,074	16,747	14,240	12,682	11,888	9,913	9,823	9,048	8,386	7,477	7,806	8,188	8,050

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2018	FY2017	FY2016	FY2015	FY2010	FY2009	FY2008
Total allocated to reportable segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Cardiovascular	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
MedSurg	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Rhythm and Neuro	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Rhythm Management	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Manufacturing Operations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and Currency Exchange	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Boston Scientific Corporation (BSX) revenue by segment, product and region

Where the money comes from and where it goes

Revenue by product or service $m

Operating income by segment $m, and margin

Revenue by segment $m

Operating income by segment $m, and margin

Stockrow Weekly